Search bioRxiv⌕ Search

Biology subjects

taye, m.

Publications and source records attributed to taye, m..

2 recordsLinked to original sources

Biological Time Equivalence in Vertebrates: Thermodynamic Framework, Comparative Tests, and Clade-Specific Deviations

Across adult warm-blooded vertebrates, the product of resting heart rate fH and maximum lifespan L is approximately constant: N[*] = fH L {approx} 109 cardiac cycles. This empirical regularity, noted since Rubner (1908), has lacked a widely accepted thermodynamic interpretation. We derive N[*] {approx} 109 from the non-equilibrium second law by treating the adult organism as a metabolic non-equilibrium steady state (NESS) and introducing the empirical closure[e] p ={sigma} 0f, which links entropy production rate to heart rate via a mass-specific parameter{sigma} 0 {propto} M0. Under this closure, the lifetime entropy budget {sum} ={sigma} 0N[*] is approximately species-independent when{sigma} 0 is approximately constant--a condition whose direct calorimetric verification remains the critical outstanding experimental test. We further show that N[*] is the correct primitive invariant: lifetime energy per unit mass is a derived consequence, valid only when body temperature and the mass-specific entropy cost per cycle are both approximately constant. This framework, which we term the Principle of Biological Time Equivalence (PBTE), is placed on a fully falsifiable footing with explicit assumptions, a domain-of-validity table, and five numerical falsification criteria. We test the framework against a dataset of 230 adult vertebrate species spanning eight taxonomic groups. Ordinary least-squares regression on the n = 43 directly measured non-primate placentals yields slope [Formula] (R2 = 0.863; F -test p = 0.093 against {beta} = -1). Phylogenetically independent contrasts on 112 endotherm species yield a log10 fH-log10 L slope of -0.99 {+/-} 0.04 (p = 0.84 against slope -1), confirming the relation is not a phylogenetic artefact. The WBE kinematic null of zero inter-clade variation is rejected (F = 12.7, p < 0.001). Four warm-blooded clades depart systematically from the mammalian baseline; we derive their longevity deviations from a unified thermodynamic multiplier {Phi}C = {Phi}duty {middle dot} {Phi}thermal {middle dot} {Phi}mito+oxid {middle dot} {Phi}haz, calibrated to independently measured physiology. For primates, the elevated count [<]N[*][>] {approx} (2-3) x 109 follows from a neuro-metabolic entropy model in which greater neural metabolic investment reduces entropy produced per cardiac cycle. For bats, the extreme longevity ({Phi}bat {approx} 7.9) arises from the multiplicative synergy of cardiac suppression during torpor and an Arrhenius thermal factor during hibernation--two mechanisms acting simultaneously whose thermodynamic motivation has not previously been given. For birds, an adverse thermal penalty ({Phi}thermal = 0.73) and adverse flight duty cycle ({Phi}duty = 0.87) are overcome by mitochondrial coupling efficiency and antioxidant robustness. For cetaceans, extreme diving bradycardia ({Phi}duty = 3.08 for bowhead whales) reveals a near-coincidence trap: the raw heartbeat count Nobs {approx} N0 conceals a true thermodynamic budget three times the mammalian baseline. Within this framework, the integral of physiological frequency defines a natural biological proper time, which unifies all longevity mechanisms as Class 1 (time dilation: reduce f ) or Class 2 (budget expansion: reduce{sigma} 0), generating testable predictions for epigenetic aging clocks. The central outstanding experimental requirement is direct calorimetric verification of{sigma} 0 {propto} M0, which would convert PBTE from a statistically supported regularity with thermodynamic motivation into a fully tested conservation law.

systems biology↗

Drug Washout and Viral Rebound: Modeling HIV Reactivation Under ART Discontinuation

Due to the persistence of latently infected CD4+ T cells, achieving a functional cure for HIV-1 remains a significant challenge since the viruses are able to evade immune clearance, which in turn enables post-treatment viral rebound. Because traditional deterministic models assume a constant reactivation rate, they fail to capture the stochastic nature of latency reversal influenced by immune perturbations and ART pharmacokinetics. Thus, in this study, by using a Poisson-driven stochastic framework that incorporates fluctuations in activation rates, we study viral rebound dynamics. Via an exponentially decreasing drug washout model, we accurately quantifies the nonlinear interplay between ART decay and stochastic reactivation, improving the theoretical estimates of post-treatment control. Beyond the introduction of stochasticity, our model establishes a time-dependent viral reactivation framework that integrates periodic and random perturbations in the activation rates. Unlike conventional models that assume uniform (temporally independent reactivation), we show that latency reversal follows structured oscillatory patterns modulated by immune cycles, circadian rhythms, and transient inflammatory episodes. This finding suggests that viral rebound risk is dynamically shaped by immune fluctuations, contrary to the assumption of a constant reactivation probability. We also study the model system by incorporating Gamma-distributed waiting times to account for heterogeneity in reactivation kinetics, which in turn provides a more flexible characterization of reservoir dynamics. We believe that these insights have critical implications for HIV cure strategies. For instance, the shock-and-kill approach relies on latency-reversing agents (LRAs) to reactivate the latent reservoir for immune-mediated clearance. Our findings suggest that periodic immune stimulation could enhance viral clearance, which indicates that synchronizing LRA administration with immune activation cycles may improve therapeutic efficacy. Furthermore, by coupling stochastic reactivation dynamics with ART pharmacokinetics, we identify optimized treatment interruption protocols that potentially delays viral rebound and extending ART-free remission. Moreover, this framework offers a generalizable model for chronic viral infections beyond HIV, including hepatitis B virus (HBV) and cytomegalovirus (CMV) since immune fluctuations and stochastic reactivation play a central role in viral persistence. By expanding theoretical models to incorporate dynamic reactivation rates, immune perturbations, and pharmacokinetic decay, our study refines the predictive modeling of post-treatment control and provides a mathematical foundation for optimizing cure strategies in persistent viral infections. Additionally, we show that the efficacy of latency-reversing interventions, such as the Shock-and-Kill strategy, can be enhanced by synchronizing latency reversal with peak immune activity, improving post-treatment control. Beyond HIV, our framework provides a generalizable model for other persistent viral infections, including hepatitis B virus (HBV) and cytomegalovirus (CMV), offering valuable insights into the interplay between immune dynamics, drug decay, and viral reactivation. PACS numbersValid PACS appear here

biophysics↗